and reports other support from Travere Therapeutics Inc, the Doris Duke Charitable Foundation, Bayer AG, AstraZeneca, Novo Nordisk, The George Institute for Global Health, CareDx and KBP BioSciences, and personal fees from Boehringer Ingelheim, Bayer Pharmaceuticals and Eli Lilly
Isogenic mutants deficient in the activities of thioredoxin (54), catalase (KatA) (55), NADPH quinone reductase (56), and superoxide dismutase (46) are sensitive to host colonization and susceptible to oxidative damage
published dosage figures refer to experimental animal/in-vitro studies, not human protocols
The therapy has been shown to provide benefits such as accelerated recovery, improved sleep, increased energy, enhanced metabolism, healthier skin, stronger immunity, sharper focus, and balanced hormones with better libido